VCEL - Vericel Corporation

Vericel Corporation develops and commercializes advanced cell therapies, with its primary products being MACI (matrix-induced autologous chondrocyte implantation) for cartilage repair in the knee and Epicel (cultured epidermal autografts) for severe burn treatment. The business model is specialty biologic sales to orthopedic surgeons and burn centers in the United States, with a direct sales force targeting hospital and ambulatory surgical center accounts. Vericel generates approximately $250M in annual revenue, almost entirely from the U.S. market, with MACI accounting for the large majority of sales and Epicel serving a smaller, life-saving niche.

Past Year Trends

• VCEL's MACI cartilage repair product delivered 21% revenue growth to $239.5 million in FY2025, driven by a completed sales force expansion and record surgeon adoption (~1,000 trained arthroscopic surgeons), sustaining four consecutive quarters of 20%+ growth into Q1 2026. (Bullish)
• Vericel's Epicel burn care segment accelerated sharply, with Q1 2026 revenue surging 91% year-over-year to $12.0 million and biopsies growing 38%, reversing a period of flat burn care performance and signaling a new phase of commercial momentum. (Bullish)
• Vericel received a BARDA contract award valued at up to $197 million for NexoBrid procurement and advanced development, providing a significant non-dilutive revenue stream and validating the product's role in the U.S. burn care infrastructure. (Bullish)

Next Year Trends

• The FDA-approved new MACI manufacturing facility in Burlington, Massachusetts began production in Q2 2026, removing a supply constraint that previously capped growth; successful ramp-up would directly underpin the company's 2026 revenue guidance of $316–$326 million, but any manufacturing qualification delays would pressure near-term MACI supply. (Bullish)
• The MASCOT randomized controlled trial, initiated in Q4 2025, is evaluating MACI in ankle cartilage repair versus bone marrow stimulation; a positive readout would unlock a meaningful label expansion into an underpenetrated adjacent indication, while trial delays or negative data would remove a key re-rating catalyst. (Bullish)
• Vericel plans to submit a UK MHRA marketing authorization application for MACI in 2026, targeting a 2027 commercial launch; success would open the first international market for MACI, but regulatory timelines in the UK post-Brexit introduce execution risk that could push the launch into 2028. (Neutral)

Red Flags

No severe red flags identified as of August 2025.